Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali

Bocar Baya*, Chad J Achenbach, Bourahima Kone, Yacouba Toloba, Djeneba K. Dabitao, Bassirou Diarra, Drissa Goita, Seydou Diabaté, Mamoudou Maiga, Dianguina Soumare, Khadidia Ouattara, Tenin Kanoute, Gaoussou Berthe, Youssouf M. Kamia, Yeya dit Sadio Sarro, Moumine Sanogo, Antieme C.G. Togo, Bindongo P.P. Dembele, Nadie Coulibaly, Amadou KoneMaxwell Akanbi, Michael Belson, Sounkalo Dao, Susan Orsega, Sophia Siddiqui, Seydou Doumbia, Robert Leo Murphy, Souleymane Diallo

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF ® has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali. Methods: We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS. Results: We found that age ≤40 years (OR = 2.56. 95% CI: 1.44–4.55), two courses of prior TB treatment (OR = 3.25, 95% CI: 1.44–7.30), TB treatment failure (OR = 3.82, 95% CI 1.82–7.79), sputum microscopy with 3+ bacilli load (OR = 1.98, 95% CI: 1.13–3.48) and a history of contact with a TB patient (OR = 2.48, 95% CI: 1.11–5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR = 0.88, 95% CI: 0.34–1.94). Conclusion: We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.

Original languageEnglish (US)
Pages (from-to)149-155
Number of pages7
JournalInternational Journal of Infectious Diseases
Volume81
DOIs
StatePublished - Apr 1 2019

Fingerprint

Mali
Multidrug-Resistant Tuberculosis
Sputum
Treatment Failure
Drug Resistance
Teaching Hospitals
Bacillus
Microscopy
Cross-Sectional Studies
Odds Ratio
HIV
Prospective Studies

Keywords

  • Mali
  • Multi-Drug Resistant Tuberculosis
  • Risk factors

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Baya, Bocar ; Achenbach, Chad J ; Kone, Bourahima ; Toloba, Yacouba ; Dabitao, Djeneba K. ; Diarra, Bassirou ; Goita, Drissa ; Diabaté, Seydou ; Maiga, Mamoudou ; Soumare, Dianguina ; Ouattara, Khadidia ; Kanoute, Tenin ; Berthe, Gaoussou ; Kamia, Youssouf M. ; Sarro, Yeya dit Sadio ; Sanogo, Moumine ; Togo, Antieme C.G. ; Dembele, Bindongo P.P. ; Coulibaly, Nadie ; Kone, Amadou ; Akanbi, Maxwell ; Belson, Michael ; Dao, Sounkalo ; Orsega, Susan ; Siddiqui, Sophia ; Doumbia, Seydou ; Murphy, Robert Leo ; Diallo, Souleymane. / Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. In: International Journal of Infectious Diseases. 2019 ; Vol. 81. pp. 149-155.
@article{de570a06ad7546eb99a3aeb96e2cd09a,
title = "Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali",
abstract = "Background: MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF {\circledR} has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali. Methods: We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS. Results: We found that age ≤40 years (OR = 2.56. 95{\%} CI: 1.44–4.55), two courses of prior TB treatment (OR = 3.25, 95{\%} CI: 1.44–7.30), TB treatment failure (OR = 3.82, 95{\%} CI 1.82–7.79), sputum microscopy with 3+ bacilli load (OR = 1.98, 95{\%} CI: 1.13–3.48) and a history of contact with a TB patient (OR = 2.48, 95{\%} CI: 1.11–5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR = 0.88, 95{\%} CI: 0.34–1.94). Conclusion: We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.",
keywords = "Mali, Multi-Drug Resistant Tuberculosis, Risk factors",
author = "Bocar Baya and Achenbach, {Chad J} and Bourahima Kone and Yacouba Toloba and Dabitao, {Djeneba K.} and Bassirou Diarra and Drissa Goita and Seydou Diabat{\'e} and Mamoudou Maiga and Dianguina Soumare and Khadidia Ouattara and Tenin Kanoute and Gaoussou Berthe and Kamia, {Youssouf M.} and Sarro, {Yeya dit Sadio} and Moumine Sanogo and Togo, {Antieme C.G.} and Dembele, {Bindongo P.P.} and Nadie Coulibaly and Amadou Kone and Maxwell Akanbi and Michael Belson and Sounkalo Dao and Susan Orsega and Sophia Siddiqui and Seydou Doumbia and Murphy, {Robert Leo} and Souleymane Diallo",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.ijid.2019.02.004",
language = "English (US)",
volume = "81",
pages = "149--155",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",

}

Baya, B, Achenbach, CJ, Kone, B, Toloba, Y, Dabitao, DK, Diarra, B, Goita, D, Diabaté, S, Maiga, M, Soumare, D, Ouattara, K, Kanoute, T, Berthe, G, Kamia, YM, Sarro, YDS, Sanogo, M, Togo, ACG, Dembele, BPP, Coulibaly, N, Kone, A, Akanbi, M, Belson, M, Dao, S, Orsega, S, Siddiqui, S, Doumbia, S, Murphy, RL & Diallo, S 2019, 'Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali', International Journal of Infectious Diseases, vol. 81, pp. 149-155. https://doi.org/10.1016/j.ijid.2019.02.004

Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. / Baya, Bocar; Achenbach, Chad J; Kone, Bourahima; Toloba, Yacouba; Dabitao, Djeneba K.; Diarra, Bassirou; Goita, Drissa; Diabaté, Seydou; Maiga, Mamoudou; Soumare, Dianguina; Ouattara, Khadidia; Kanoute, Tenin; Berthe, Gaoussou; Kamia, Youssouf M.; Sarro, Yeya dit Sadio; Sanogo, Moumine; Togo, Antieme C.G.; Dembele, Bindongo P.P.; Coulibaly, Nadie; Kone, Amadou; Akanbi, Maxwell; Belson, Michael; Dao, Sounkalo; Orsega, Susan; Siddiqui, Sophia; Doumbia, Seydou; Murphy, Robert Leo; Diallo, Souleymane.

In: International Journal of Infectious Diseases, Vol. 81, 01.04.2019, p. 149-155.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali

AU - Baya, Bocar

AU - Achenbach, Chad J

AU - Kone, Bourahima

AU - Toloba, Yacouba

AU - Dabitao, Djeneba K.

AU - Diarra, Bassirou

AU - Goita, Drissa

AU - Diabaté, Seydou

AU - Maiga, Mamoudou

AU - Soumare, Dianguina

AU - Ouattara, Khadidia

AU - Kanoute, Tenin

AU - Berthe, Gaoussou

AU - Kamia, Youssouf M.

AU - Sarro, Yeya dit Sadio

AU - Sanogo, Moumine

AU - Togo, Antieme C.G.

AU - Dembele, Bindongo P.P.

AU - Coulibaly, Nadie

AU - Kone, Amadou

AU - Akanbi, Maxwell

AU - Belson, Michael

AU - Dao, Sounkalo

AU - Orsega, Susan

AU - Siddiqui, Sophia

AU - Doumbia, Seydou

AU - Murphy, Robert Leo

AU - Diallo, Souleymane

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF ® has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali. Methods: We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS. Results: We found that age ≤40 years (OR = 2.56. 95% CI: 1.44–4.55), two courses of prior TB treatment (OR = 3.25, 95% CI: 1.44–7.30), TB treatment failure (OR = 3.82, 95% CI 1.82–7.79), sputum microscopy with 3+ bacilli load (OR = 1.98, 95% CI: 1.13–3.48) and a history of contact with a TB patient (OR = 2.48, 95% CI: 1.11–5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR = 0.88, 95% CI: 0.34–1.94). Conclusion: We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.

AB - Background: MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF ® has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali. Methods: We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS. Results: We found that age ≤40 years (OR = 2.56. 95% CI: 1.44–4.55), two courses of prior TB treatment (OR = 3.25, 95% CI: 1.44–7.30), TB treatment failure (OR = 3.82, 95% CI 1.82–7.79), sputum microscopy with 3+ bacilli load (OR = 1.98, 95% CI: 1.13–3.48) and a history of contact with a TB patient (OR = 2.48, 95% CI: 1.11–5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR = 0.88, 95% CI: 0.34–1.94). Conclusion: We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.

KW - Mali

KW - Multi-Drug Resistant Tuberculosis

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85062150898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062150898&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2019.02.004

DO - 10.1016/j.ijid.2019.02.004

M3 - Article

C2 - 30772470

AN - SCOPUS:85062150898

VL - 81

SP - 149

EP - 155

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

ER -